Navigation Links
New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery
Date:3/31/2009

NEW YORK, March 31 /PRNewswire/ -- Transdermal delivery of estrogen therapy available by prescription "seems not to alter" the risk of venous thromboembolism (VTE), or blood clotting, in postmenopausal patients when compared to oral delivery, a new study suggests. The study was conducted by researchers at NYU Langone Medical Center and was published in the latest issue of Menopause: The Journal of the North American Menopause Society.

Prescription transdermal estrogen therapy is bioidentical to estrogen produced by a woman's ovaries before menopause and delivered through the skin. Transdermal estrogen is available in a variety of formulations which have been quality controlled and approved safe and effective by the United States Food and Drug Administration (FDA).

The team at NYU Langone sought to determine the effects of delivery of estrogen therapy on postmenopausal women. Blood obtained from 84 postmenopausal women was tested for clotting activity before and after administration of oral or transdermal estrogen for a period of eight weeks. Women with borderline clotting issues showed "a significant acceleration" of clotting after oral estrogen therapy, but no significant change after transdermal estrogen therapy.

"Venous thromboembolic complications or blood clots represent an established risk factor of estrogen therapy, and evidence is now mounting that the route of estrogen administration influences this risk," said researcher Lila Nachtigall, M.D., Director of the Women's Wellness Program at NYU. "These new data on the safety of transdermal HT delivery may prove to be useful information for postmenopausal women deciding whether to take estrogen therapy and whether to take it orally or through the skin."

The research team studied platelet activity in the study participants' blood. Platelets serve a central role in forming pathological arterial thrombosis tha
'/>"/>

SOURCE NYU Langone Medical Center
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...and,Nov.25/PRNewswire/-- FromNovember16-18,Phonak,...,presentedthesecondeditionoftheHearingCareforAdult...ulation.Theconferencebroughttogetherleadingexperts...0clinicianswhoworkeverydaywitholderpeoplewithheari...thelatestresearchandtrendsinhearingcareforolderpeo...
(Date:11/25/2009)....25/PRNewswire/--AMPACFineChemicalsLLC(AFC),asubsi...nouncedtodaythatitreceivedtheEnvironmentalResponsi...vironmentalSummit,sponsoredbytheCaliforniaManufact...nvironmentalAssociation(IEA)andtheChemicalIndustry...ostprestigiousawardavailablefromallthreeorganizati...
(Date:11/25/2009)...PRNewswire-FirstCall/--Abaxis,Inc.(Nasdaq: ABAX ),...loodanalysissystems,announcedtodaythatClintSeverso...e21stAnnualPiperJaffrayHealthCareConferenceonWedne...eheldattheNewYorkPalaceHotelinNewYorkCity. ,, ...arketsportablebloodanalysissystemsforuseinanyveter...
Breaking Medicine Technology:Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2OPEBAnswers com Launched to Help Government Entities Solve Their OPEB Issues 59745 1Allied Worlds Susan Chmieleski to Speak at American Society for Healthcare Risk Management 28ASHRM 29 Annual Conference and Exhibition 59740 1Allied Worlds Susan Chmieleski to Speak at American Society for Healthcare Risk Management 28ASHRM 29 Annual Conference and Exhibition 59740 2Allied Worlds Susan Chmieleski to Speak at American Society for Healthcare Risk Management 28ASHRM 29 Annual Conference and Exhibition 59740 3For the First Time Blood Donors May Answer Their Health History Questions Online From the Privacy of Their Home or Office 5564 1For the First Time Blood Donors May Answer Their Health History Questions Online From the Privacy of Their Home or Office 5564 2
...DENVER--(BUSINESS WIRE)--Mar 12, 2007 - Ceragenix ...tical company focused on,infectious disease and de... with a Ceragenin compound demonstrated virtually ...udy, polyurethane catheters treated with Ceragenin...on along with an,untreated catheter. At day 21, th...
... HILLSIDE, NJ, March 12, 2007—InB:Biotechnol... of Integrated BioPharma,Inc. (NASDAQ: INBP), tod... vaccines against HPV, anthrax and plague made usi... technology. The,studies were conducted by the Fra...B), the Contract Research Organization led by Dr.,...
Other Medicine Technology:Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3Integrated BioPharma's Proprietary Vaccine Technology Achieves,Strong Positive Results 2
(Date:11/25/2009)...VILLE,Calif.,Nov.25/PRNewswire-FirstCall/-- OnyxP...atthecompanywillhosttwoinvestoreventsinDecember: ,...m.CT/10:00a.m.ET ,, Principalinvestigatorswil...elapsedand/orrefractorymultiplemyeloma,asfeatureda...ingandExpositioninNewOrleans,LA.Theteleconferencew...
(Date:11/25/2009)...RSPRING,Md.,Nov.25/PRNewswire-USNewswire/--Anartic...DrugEvaluationandResearch,titled"ADifficultBalance...Nov.26,2009issueofTheNewEnglandJournalofMedicine. ...0090824/FDALOGO ) ,, Inthearticle,Woodcockdiscu...edicationforthosewhoneeditandmanagingtherisksposed...
(Date:11/25/2009)...urvivors of testicular cancer who were treated wit...e effects, including neurological side effects and...ated with chemotherapy, according to a new study p... National Cancer Institute . , Marianne Brydy, M...ersity Hospital, in Bergen, Norway, and colleagues...
(Date:11/25/2009)...low-up period was too short to draw definite concl.... 25 (HealthDay News) -- In diabetic patients with... difference in outcomes at one year whether patien...ting, British researchers report. , Bypass surg...atients with coronary artery disease. However, les...
(Date:11/25/2009)...en plagued by neurological symptoms, study finds ...-- Neurological side effects are among the potenti...ular cancer who were treated with cisplatin-based ...y included 1,409 Norwegian men treated for unilate...ok part in a follow-up survey conducted from 1998 ...
Breaking Medicine News(10 mins):Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3
... 4,000 Australian children are to be weighed, meas...ional survey designed to tackle //the growing mena...artment said that about 25 percent of the children...inister Tony Abbott said that 4,000 children would...
...ternational Distinguished Fellow and Director of t...vy Carroll, Ph.D., has been presented //the Colleg...Eddy Memorial Award for outstanding research in th..., Carroll developed RTI-336 and JDTic, two pharmac...
...chers at the Johns Hopkins University were fruitfu...sa (RP) using the combination of chemicals such// ...ant. Experiments using mice in the treatment o...ochiaro, the Eccles Professor of Ophthalmology and...
...research conducted by consumer organization Which?...contain high levels of fat, salt and sugar. Of t...cked for sugar, salt and fat content using the Foo...igh level of saturated fat. The findings a...
...ed for regulation of infertility clinics has been ...terday in the 'embryo' case according to Senator M...a medical doctor, had put forward a private member...n reproduction in Ireland. According to the ...
...st 18 people, mostly children and women, have died... of Lakhimpur and Dhemaji since the beginning of t...ere, 14 people died of the disease in Lakhimpur di...ion swung into action to take preventive measures,...
Other Medicine News:Health News:Scientist Recognized for Drug Addiction Research 2Health News:Antioxidants Preserve Cone Cells In the Eye 2Health News:Regulation of Infertility Clinics Needed 2
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
Medicine Products: